Ajouter à une liste

Communiqués Poltreg S.A.

Actions

PTG

PLPLTRG00038

Recherche biotechnologique et médicale

Temps Différé Warsaw S.E. 15:22:58 07/09/2026			Varia. 5j.	Varia. 1 janv.
23,20 ^PLN	+5,94%		-1,28%	-5,31%

11/05	Poltreg S.A. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
06/05	Poltreg S.A. publie ses résultats annuels pour l'exercice clos au 31 décembre 2025	CI

Communiqués

11/03	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1	GL
10/03	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
07/11	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
04/08/25	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
31/07/25	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
04/07/25	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL
13/06/25	PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	GL
15/05/25	Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes	GL
24/10/24	PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes	AQ
26/09/24	PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases	AQ
16/09/24	China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis	AQ
09/09/24	PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence	AQ
24/06/24	PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years	AQ
04/04/24	PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab	AQ
11/03/24	PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland	AQ
21/02/24	PolTREG appoints Dan Shelly as Chief Business Development Officer	AQ
30/01/24	PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy	AQ
16/01/24	PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT